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Summary
Background The WHO Global Health Sector Strategy aims to reduce worldwide syphilis incidence by 90% between 
2018 and 2030. If this goal is to be achieved, interventions that target high-burden groups, including men who have 
sex with men (MSM), will be required. However, there are no global prevalence estimates of syphilis among MSM to 
serve as a baseline for monitoring or modelling disease burden. We aimed to assess the global prevalence of syphilis 
among MSM using the available literature.
Methods In this global systematic review and meta-analysis, we searched MEDLINE, Embase, LILACS, and AIM 
databases, and Integrated Bio-Behavioral Surveillance (IBBS) reports between April 23, 2019, and Feb 1, 2020, to 
identify studies done between Jan 1, 2000, and Feb 1, 2020, with syphilis point prevalence data measured by biological 
assay among MSM (defined as people who were assigned as male at birth and had oral or anal sex with at least one 
other man in their lifetime). Studies were excluded if participants were exclusively HIV-infected MSM, injection-
drug users, only seeking care for sexually transmitted infections (STIs) or genital symptoms, or routine STI clinic 
attendees. Data were extracted onto standardised forms and cross-checked for accuracy and validity. We used 
random-effects models to generate pooled prevalence estimates across the eight regions of the Sustainable 
Development Goals. We calculated risk of study bias based on the Appraisal tool for Cross-Sectional Studies, and 
stratified results based on low versus high risk of bias. This systematic review and meta-analysis was registered with 
PROSPERO, CRD42019144594.
Findings We reviewed 4339 records, 228 IBBS reports, and ten articles from other sources. Of these, 1301 duplicate 
records were excluded, 2467 records were excluded after title and abstract screening, and 534 articles were excluded 
after full-text analysis. We identified 345 prevalence data points from 275 studies across 77 countries, with a total of 
606 232 participants. Global pooled prevalence from 2000–20 was 7·5% (95% CI 7·0–8·0%), ranging from 1·9% 
(1·0–3·1%) in Australia and New Zealand to 10·6% (8·5–12·9%) in Latin America and the Caribbean.
Interpretation Unacceptably high syphilis prevalence among MSM warrants urgent action.
Funding Wellcome Trust.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
WHO routinely produces global estimates of curable 
sexually transmitted infections among men and women 
to provide policy makers and programme managers 
with evidence that can be used to tailor interventions 
and to enhance programme monitoring and evaluation. 
Syphilis is a curable sexually transmitted infection (STI) 
caused by Treponema pallidum, a motile Gram-negative 
spirochaete. The most recent global prevalence estimate 
from WHO for syphilis was 0·51% (uncertainty interval 
0·43–0·60) among men in 2016.1 Stratified by regions of 
the Sustainable Development Goals (SDGs) as led by 
the UNDP, syphilis prevalence for men in the general 
population ranges from 0·01% (0·0–0·02) in Australia 
and New Zealand to 5·18% (2·83–7·54) in Oceania.1 
However, syphilis can disproportionately affect men 
who have sex with men (MSM) due to sexual-network 
dynamics that include high-risk sexual practices, 
multiple sex partners, and concurrent use of controlled 
substances.2,3
In 2016, the 69th World Health Assembly adopted 
three Global Health Sector Strategies to guide the 
health-sector response to the SDGs. The strategy 
addressing STIs describes four ambitious targets, one 
of which is to reduce global syphilis incidence by 90% 
from 2018 to 2030.4 To achieve this goal, countries will 
need to prioritise reducing syphilis among high-burden 
groups including MSM. Moreover, reports of increasing 
syphilis infection among MSM in countries including 
Australia,5 New Zealand,6 South Korea,7 the UK,8 and 
the USA9 are cause for concern and action. Efforts to 
collate MSM prevalence data would help countries and 
the global community to set priorities. We therefore 
aimed to assess the global prevalence of syphilis among 
MSM using the available literature.
Methods
Search strategy and selection criteria
In this global systematic review and meta-analysis, 
we searched MEDLINE, Embase, LILACS, and AIM 
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databases between April 23, 2019, and Feb 1, 2020, 
without language restriction, for studies done between 
Jan 1, 2000, and Feb 1, 2020. Search terms were 
combinations of syphilis related words (eg, “syphilis”, 
“Treponema pallidum”), sexuality related terms (eg, “gay”, 
“men who have sex with men”), and the names of each of 
the 235 countries and territories (one by one) based on 
SDG regional groupings.10 We tested the search strategy 
through an iterative process before finalising our 
combinations of terms (appendix p 38). We identified 
additional point prevalence data by reviewing reference 
lists from papers that met our inclusion criteria and 
searching the Key Populations Atlas11 and Integrated Bio-
Behavioral Surveillance (IBBS) reports from UNAIDS. 
We inquired with corresponding authors to fill in 
information gaps if key details were not contained in the 
full publication.
We defined MSM as individuals who were assigned as 
male at birth and had oral or anal sex with at least one 
other man in their lifetime. Eligible studies included 
bisexual men and transgender individuals, and reported 
crude syphilis prevalence data based on a biological 
assay. Studies were excluded if participants were 
exclusively HIV-infected MSM, injection-drug users, 
only seeking care for STIs or genital symptoms, or 
routine STI clinic attendees. These studies would have 
introduced selection bias and skewed pooled prevalence 
estimates higher. We followed the PRISMA checklist 
(appendix pp 22–23) and registered our study with 
PROSPERO, CRD42019144594. 
Data analysis
The first author (MT) screened titles and abstracts of 
articles on the basis of eligibility criteria and then 
extracted relevant information onto a standardised data 
extraction form (appendix p 39). Two other coauthors 
(EPD and JE) reviewed all data extraction forms alongside 
full-text articles, cross-checking for accuracy and validity. 
Non-English articles were also reviewed. Discrepancies 
between the full-text and data extraction form were 
discussed by these three researchers. If consensus could 
not be reached, the last author (RMC) served as arbiter 
and made a final determination.
Various diagnostic methods were used across studies 
reporting point prevalence data, each representing a 
different degree of diagnostic accuracy (appendix p 24). If 
a study used more than one diagnostic test, we chose 
data from qualitative diagnostic methods that were based 
on a combination of non-treponemal and treponemal 
tests. If a study used an assay that has a reported range 
of sensitivity or specificity, we selected the midpoint 
measure. We then applied a standard method for 
correcting diagnostic errors for all point prevalence data 
using the sensitivities and specificities of individual 
Research in context
Evidence before this study 
We searched MEDLINE, Embase, LILACS, and AIM databases, 
and the Key Population Atlas and Integrated Bio-Behavioral 
Surveillance reports from UNAIDS, without language 
restriction, to identify point prevalence estimates of syphilis 
based on biological assays between April 23, 2019, and 
Feb 1, 2020, to identify studies done between Jan 1, 2000, 
and Feb 1, 2020, that contained syphilis point prevalence data 
among men who have sex with men (MSM). We combined 
syphilis related word (eg, “syphilis”, “Treponema pallidum”), 
sexuality related terms (eg, “gay”, “men who have sex with 
men”), and individual names of 235 countries and territories 
(one by one) worldwide that constitute the regional groupings 
of the Sustainable Development Goals. We found no existing 
systematic reviews of global pooled prevalence estimates of 
syphilis among MSM. 
Added value of this study 
To the best of our knowledge, this is the first systematic review 
and meta-analysis of global syphilis prevalence among MSM. We 
provide pooled prevalence estimates of syphilis in MSM for the 
eight regions of the Sustainable Development Goals and six WHO 
regions over 20 years. Our results underscore the 
disproportionately high burden of syphilis in MSM. The most 
recent global estimate for syphilis among men in the general 
population was from 2016, at 0·5% (uncertainty interval 
0·4–0·6) with regional values ranging from 0·01% to 5·18%. By 
contrast, our global estimate for MSM was 7·5% (95% CI 7·0–8·0) 
with regional values ranging from 1·9% to 10·6%. We also 
present global pooled prevalence estimates stratified by country 
income level according to World Bank classifications (low, lower-
middle, upper-middle, and high), HIV prevalence of study 
participants (>5% vs ≤5%), subgroups of MSM (studies 
exclusively with male sex workers, transgender women, and 
transgender women sex workers vs other MSM studies), in-
country legality of same-sex acts, sampling methods used 
(snowball sampling, respondent-driven sampling, time-location 
sampling, voluntary counselling and testing, probability 
sampling, and convenience sampling), diagnostic methods used 
(qualitative vs quantitative methods), sample size 
(>500 vs ≤500), and risk of study bias based on the Appraisal tool 
for Cross-Sectional Studies (low vs high risk of bias). 
Implications of all the available evidence 
The global syphilis prevalence among MSM from 2000–20 is 
alarmingly high. To reduce syphilis incidence 90% globally from 
2018 to 2030, as per the Global Health Sector Strategy, will 
require interventions that target MSM with high rates of annual 
screening and treatment for syphilis, particularly in lower-
middle, upper-middle, and high-income countries where cases 
appear to be increasing, and where HIV prevalence in MSM is 
greater than 5%.
See Online for appendix
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assays (appendix pp 24, 40).12 The method allowed for 
standardising point estimates on the basis of a common 
definition (the WHO-recommended standard of active 
syphilis, defined as positivity on both a treponemal and 
non-treponemal test).13 We then applied these corrected 
point prevalence data to random-effects models using 
the metaprop command14 in Stata, which is capable of 
incorporating proportions close to or at the margins, ie, 
very low or very high prevalence data, into pooled 
prevalence estimates and 95% CIs.14 We stratified results 
into the eight SDG regions and the six WHO regions 
(appendix pp 3–11, 25–26). We assessed heterogeneity 
between studies by subgroup analyses using the χ² test 
with Cochran’s Q statistic and quantified with I².15,16 
We further explored whether observed differences in the 
corrected prevalence estimates could be explained by 
other factors using multivariate random-effect meta-
regression, adjusting for all the variables of interest. All 
statistical analyses were done using Stata/IC version 16.1.
We did several subgroup analyses, stratifying syphilis 
prevalence estimates by 10-year periods (2000–09 and 
2010–20) and then 5-year periods (2000–04, 2005–09, 
2010–14, 2015–20). We stratified the global pooled 
prevalence estimates of syphilis by country income level 
according to World Bank classifications (low, lower-
middle, upper-middle, and high),17 HIV prevalence of 
study participants corrected using the same methods as 
that for syphilis (>5% vs ≤5%; appendix p 27), subgroups 
of MSM (studies exclusively with male sex workers, 
transgender women, and transgender women sex 
workers vs other MSM studies), legality of same-sex 
sexual acts in the country from where data came (legal 
vs illegal),18 sampling methods used (snowball sampling, 
respondent-driven sampling, time-location sampling, 
voluntary counselling and testing, probability sampling, 
and convenience sampling), diagnostic methods used 
(qualitative [without cutoff titre value of non-treponemal 
test] vs quantitative [with the value of non-treponemal 
test]), sample size (>500 vs ≤500), and scoring for risk of 
study bias on the basis of the Appraisal tool for Cross-
Sectional Studies (AXIS, high risk [0–10] vs low risk 
[11–20]; appendix p 41).19,20 Categories of income level 
and legality of same-sex sexual acts were based on 
circumstances within each country or territory at the 
midpoint of the study period. We further assessed how 
inclusion or exclusion of each subgroup influenced our 
overall estimates as a sensitivity analysis.
Role of the funding source
There was no direct funding source for this study.
Results
We identified 4339 records through searches of 
MEDLINE, Embase, LILACS, and AIM databases. We 
also reviewed 228 IBBS reports and obtained ten articles 
from other sources. In total, we found 275 eligible studies 
that contained 345 data points for meta-analysis (figure 1).
Global and SDG regional pooled prevalence estimates 
from 2000–20, 2010–20, and 2000–09 are presented in 
table 1 and figure 2. Pooled prevalence estimates stratified 
by SDG region into 5-year intervals can be found in the 
appendix (p 28). Pooled prevalence estimates by country 
are shown in figure 3 and the appendix (p 29).
The global pooled syphilis prevalence estimate 
was 7·5% (95% CI 7·0–8·0, 345 data points; n=606 232) 
in MSM between 2000 and 2020 (table 1 and figure 2). 
Three of eight SDG regions (Latin America and 
the Caribbean, Northern Africa and Western Asia, and 
Eastern and South-Eastern Asia) had pooled prevalence 
estimates higher than the global figure. The highest 
pooled estimate was from Latin America and the 
Caribbean at 10·6% (8·5–12·9, 49 data points; n=32 316) 
and the lowest was from Australia and New Zealand 
at 1·9% (1·0–3·1, 5 data points; n=2494). The pooled 
prevalence in 2000–09 was slightly higher than that of the 
overall 20-year period, at 8·9% (8·0–9·9, 145 data points; 
n=185 877). In 2010–20, the global pooled prevalence 
was 6·6% (6·0–7·2, 200 data points; n=420 355) which is 
significantly lower than that in 2000–09 (p<0·0001). 
Three SDG regions (Northern Africa and Western Asia, 
Eastern and South-Eastern Asia, and Latin America and 
the Caribbean) had estimates above the global pooled 
estimate for 2000–09. The highest regional pooled 
estimate was 14·7% (0·0–46·6, 3 data points; n=310) in 
Figure 1: Study selection
IBBS=Integrated Bio-Behavioral Surveillance. STI=sexually transmitted infection. *Obtained from MEDLINE, 
Embase, LILACS, and AIM. †Obtained from search on UNAIDS Key Populations Atlas and consultation with 
UNAIDS.11 ‡Data that appeared in more than one record were reviewed within full-text articles. We included the 
more or most informative article in the systematic review and meta-analysis, and excluded the others.
4339 records identified from 
databases*
228 IBBS reports†
3276 records screened by title and abstract
809 full-text articles assessed for eligibility‡
275 articles included in analysis
10 articles from other sources
1301 duplicate records excluded
2467 records excluded
534 full-text articles excluded
38 STI clinic attendants only
8 conducted before 2000
342 no prevalence data
48 without sufficient data
33 review articles
60 same data in ≥2 articles‡
5 HIV-infected patients only
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Northern Africa and Western Asia, and the lowest 
was 1·0% (0·2–5·4, 1 data point; n=100) in Oceania 
(excluding Australia and New Zealand). As in 2000–09, 
three SDG regions (Latin America and the Caribbean, 
Northern Africa and Western Asia, and Eastern and 
South-Eastern Asia) had pooled prevalence estimates that 
were higher than the global prevalence estimate in 
2010–20 (table 1 and figure 2). The highest estimate was 
from Latin America and the Caribbean at 11·2% (95% CI 
8·2–14·7, 24 data points; n=16 707), and the lowest was 
from Australia and New Zealand at 1·1% (0·4–1·9, 3 data 
points; n=915). 
The pooled prevalence estimates in four SDG regions 
(Australia and New Zealand, Central and Southern 
Asia, Eastern and South-Eastern Asia, and Northern 
Africa and Western Asia) were lower in 2010–20 than 
in 2000–09. However, the pooled prevalence estimates for 
2015–20 were higher in four SDG regions (Europe and 
Northern America, Latin America and the Caribbean, 
Oceania [excluding Australia and New Zealand], and 
sub-Saharan Africa) compared with 2010–14 (appendix 
pp 12, 28).
Results from subgroup analyses are in table 2. The 
lowest pooled prevalence estimate was from low-income 
countries, at 3·8% (95% CI 2·4–5·4, 48 data points; 
n=34 440), whereas the highest pooled estimate was from 
lower-middle income countries, at 8·7% (7·7–9·7, 

































Total 52 067 606 232 (100%) 8·4% (7·9–8·9%) 7·5% (7·0–8·0%) 48 31–47 231 77 345 (100%) 98·1
Australia and New Zealand 60 2494 (0·4%) 2·0% (1·0–3·4%) 1·9% (1·0–3·1%) 6 98–1396 1 5 (1·4%) 58·4
Central and Southern Asia 2008 37 376 (6·2%) 5·5% (3·8–7·5%) 5·0% (3·3–6·9%) 22 42–11 997 8 27 (7·8%) 98·2
Eastern and South-Eastern Asia 43 872 498 371 (82·2%) 9·7% (9·1–10·2%) 9·1% (8·5-9·6%) 66 50–47 231 12 188 (54·5%) 97·6
Europe and Northern America 763 13 618 (2·2%) 5·7% (3·7–8·1%) 3·4% (1·8–5·4%) 13 31–2296 15 34 (9·9%) 96·6
Latin America and the Caribbean 4144 32 316 (5·3%) 11·4% (9·5–13·5%) 10·6% (8·5–12·9%) 54 62–5101 17 49 (14·2%) 97·5
Northern Africa and Western Asia 596 4965 (0·8%) 11·5% (5·5–19·3%) 9·6% (4·2–16·7%) 32 70–700 4 14 (4·1%) 98·2
Oceania (excluding Australia 
and New Zealand)
51 1038 (0·2%) 2·3% (0·2–5·9%) 2·3% (0·2–5·9%) 1 39–860 4 4 (1·2%) 66·3
Sub-Saharan Africa 573 16 054 (2·6%) 2·9% (1·6–4·6%) 2·1% (1·0–3·6%) 7 109–2442 16 24 (7·0%) 96·7
2010–20
Subtotal 32 366 420 355 (100%) 7·5% (6·9–8·0%) 6·6% (6·0–7·2%) 43 39–42 680 61 200 (100%) 98·0
Australia and New Zealand 11 915 (0·2%) 1·1% (0·4–1·9%) 1·1% (0·4–1·9%) 4 98–617 1 3 (1·5%) ··
Central and Southern Asia 635 20 978 (5·0%) 3·3% (2·1–4·7%) 2·8% (1·6–4·2%) 16 42–11 997 7 13 (6·5%) 95·0
Eastern and South-Eastern Asia 27 830 354 858 (84·4%) 8·3% (7·8–8·9%) 7·8% (7·2–8·4%) 71 102–42 680 9 107 (53·5%) 97·3
Europe and Northern America 570 8319 (2·0%) 6·5% (3·4–10·3%) 4·2% (1·7–7·6%) 15 43–2296 12 21 (10·5%) 97·5
Latin America and the Caribbean 2249 16 707 (4·0%) 12·2% (9·2–15·5%) 11·2% (8·2–14·7%) 52 62–5101 12 24 (12·0%) 97·5
Northern Africa and Western Asia 525 4655 (1·1%) 9·5% (3·6–17·7%) 8·4% (3·1–15·9%) 60 216–700 4 11 (5·5%) 98·4
Oceania (excluding Australia 
and New Zealand)
50 938 (0·2%) 3·0% (0·3–7·4%) 3·0% (0·3–7·4%) 1 39–860 3 3 (1·5%) ··
Sub-Saharan Africa 496 12 985 (3·1%) 3·1% (1·6–5·1%) 2·1% (0·9–3·9%) 7 109–2442 13 18 (9·0%) 97·0
2000–09
Subtotal 19 701 185 877 (100%) 9·8% (8·9–10·8%) 8·9% (8·0–9·9%) 54 31–47 231 39 145 (100%) 97.8
Australia and New Zealand 49 1579 (0·8%) 3·0% (2·2–3·9%) 2·9% (2·1–3·8%) 25 183–1396 1 2 (1·4%) ··
Central and Southern Asia 1373 16 398 (8·8%) 7·7% (4·8–11·3%) 7·2% (4·3–10·7%) 62 132–3739 4 14 (9·7%) 98·3
Eastern and South-Eastern Asia 16 042 143 513 (77·2%) 11·6% (10·6–12·7%) 11·0% (10·0–12·1%) 63 50–47 231 10 81 (55·9%) 97·1
Europe and Northern America 193 5299 (2·9%) 4·3% (2·4–6·7%) 2·1% (0·8–3·9%) 12 31–1387 7 13 (9·0%) 91·1
Latin America and the Caribbean 1895 15 609 (8·4%) 10·7% (8·1–13·6%) 9·9% (7·0–13·3%) 54 78–3280 9 25 (17·2%) 97·6
Northern Africa and Western Asia 71 310 (0·2%) 21·1% (7·7–38·7%) 14·7% (0·0–46·6%) 19 70–140 2 3 (2·1%) ··
Oceania (excluding Australia 
and New Zealand)
1 100 (0·1%) 1·0% (0·2–5·4%) 1·0% (0·2–5·4%) 1 100–100 1 1 (0·7%) ··
Sub-Saharan Africa 77 3069 (1·7%) 2·4% (0·4–5·8%) 2·1% (0·2–5·7%) 12 290–879 5 6 (4·1%) 96·3
MSM=men who have sex with men. *Heterogeneity between subgroups in all subgroup analyses was p<0·0001.
Table 1: Pooled syphilis prevalence estimates among MSM 2000–20 in regions of the Sustainable Development Goals
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syphilis, 331 (95·9%) also reported HIV prevalence. 
The pooled prevalence of syphilis was 8·7% (95% CI 
8·1–9·4, 208 data points; n=444 914) in studies where 
HIV prevalence was greater than 5%, versus 5·8% 
(4·9–6·8, 123 data points; n=153 458) in studies that 
reported an HIV prevalence of 5% or less. Pooled 
prevalence of studies exclusively among subgroups of 
MSM (male sex workers, transgender women, and 
transgender women sex workers) was 16·6% (10·4–23·9, 
18 data points; n=7096), although this represented just 
1·2% of all MSM tested. Countries where same-sex 
sexual acts are not prohibited by law had a pooled 
prevalence of 8·4% (7·9–8·9, 288 data points; n=552 674), 
compared with 3·7% (2·6–4·9, 57 data points; n=53 558) 
Figure 2: Histogram of pooled syphilis prevalence estimates among MSM, 2000–20, by regions of the Sustainable Development Goals
Error bars indicate 95% CI. MSM=men who have sex with men.
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where same-sex sexual acts are illegal. Convenience 
sampling was the most common method, accounting 
for 35·1% (121 data points) of syphilis data points 
and yielding a pooled prevalence of 7·4% (95% CI 
6·5–8·4, n=142 709). Among convenience sampling 
methods, pooled prevalence estimates based on any 
combination of multiple convenience sampling methods 
was 8·7% (7·6–9·9, 64 data points; n=109 065), followed 
by convenience sampling used by non-profit or charity 
organisations focused on the needs of MSM or that 
provide HIV prevention services, at 7·8% (5·2–10·8, 
13 data points; n=13 988), venue-specific sampling (eg, 
saunas and bathhouses, clubs, and one-off public events) 
at 6·1% (3·7–9·1, 29 data points; n=13 229), and other 
convenience sampling at 4·7% (1·4–9·4, 15 data points; 
n=6427). Time-location sampling methods produced the 
highest pooled prevalence estimate, at 12·3% (8·7–16·5, 
8 data points; n=10 359), derived from 2·3% of all data 
points. The lowest pooled prevalence estimates came 
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Low 2186 34 440 (5·7%) 4·9% (3·5–6·5%) 3·8% (2·4–5·4%) 18 99–2442 21 48 (13·9) 98·1
Lower-middle 18 711 186 450 (30·8%) 9·6% (8·6–10·6%) 8·7% (7·7–9·7%) 54 31–47 231 34 128 (37·1) 98·2
Upper-middle 30 469 372 495 (61·4%) 9·2% (8·6–9·9%) 8·6% (8·0–9·2%) 66 50–42 680 25 142 (41·2) 97·5
High 701 12 847 (2·1%) 5·8% (3·6–8·5%) 4·5% (2·6–6·9%) 15 43–2296 14 27 (7·8) 96·9
HIV prevalence
≤5% 13 496 153 458 (25·3%) 6·8% (5·9–7·8%) 5·8% (4·9–6·8%) 31 31–47 231 41 123 (35·7) 98·1
>5% 37 987 444 914 (73·4%) 9·5% (8·9–10·1%) 8·7% (8·1–9·4%) 61 43–42 680 48 208 (60·3) 98·1
Not available 584 7860 (1·3%) 6·7% (4·0–10·0%) 5·2% (2·4–8·9%) 27 83–1387 10 14 (4·1) 97·5
Subpopulation groups of MSM
Studies exclusively with male sex 
workers, transgender women, 
transgender women sex workers
1269 7096 (1·2%) 17·6% (11·5–24·6%) 16·6% (10·4–23·9%) 53 50–980 14 18 (5·2) 98·3
Other MSM study 50 798 599 136 (98·8%) 8·0% (7·5–8·5%) 7·1% (6·6–7·6%) 48 31–47 231 72 327 (94·8) 98·0
Legality of same-sex acts†
Legal 49 348 552 674 (91·2%) 9·3% (8·8–9·8%) 8·4% (7·9–8·9%) 54 31–47 231 49 288 (83·5%) 97·8
Illegal 2719 53 558 (8·8%) 4·6% (3·5–5·9%) 3·7% (2·6–4·9%) 17 39–11 997 29 57 (16·5%) 97·9
Sampling methods
Snowball sampling 32 113 366 855 (60·5%) 9·3% (8·6–10·0%) 8·5% (7·8–9·2%) 66 83–47 231 12 93 (27·0%) 97·9
Response-driven sampling 5042 67 259 (11·1%) 7·5% (6·1–9·0%) 6·7% (5·3–8·2%) 25 39–11 997 54 99 (28·7%) 98·3
Time-location sampling 1143 10 359 (1·7%) 12·4% (8·8–16·7%) 12·3% (8·7–16·5%) 90 108–3739 4 8 (2·3%) 96·7
Volunteer counselling and testing 1619 15 402 (2·5%) 7·4% (4·7–10·6%) 6·9% (4·3–10·0%) 43 90–3040 8 17 (4·9%) 97·9
Probability sampling 421 3648 (0·6%) 9·0% (3·2–17·2%) 6·0% (1·0–14·6%) 49 85–1279 7 7 (2·0%) 98·5
Convenience sampling‡ 11 729 142 709 (23·5%) 8·5% (7·5–9·4%) 7·4% (6·5–8·4%) 41 31–32 701 30 121 (35·1%) 97·8
Diagnostic methods
Qualitative methods 50 789 584 191 (96·4%) 8·7% (8·1–9·2%) 7·7% (7·1–8·2%) 53 31–47 231 74 314 (91·0%) 98·1
Quantitative methods 1278 22 041 (3·6%) 6·0% (4·3–8·1%) 6·0% (4·3–8·1%) 24 39–2276 16 31 (9·0%) 97·0
Sample size
≤500 5163 50 661 (8·4%) 8·8% (7·5–10·1%) 7·5% (6·2–8·9%) 21 31–500 59 170 (49·3%) 96·8
>500 46 904 555 571 (91·6%) 8·1% (7·6–8·7%) 7·6% (7·0–8·2%) 104 502–47 231 40 175 (50·7%) 98·6
AXIS§ score classification
Low risk of bias 47 604 551 596 (91·0%) 8·4% (7·9–9·0%) 7·5% (6·9–8·0%) 49 31–47 231 73 315 (91·3%) 98·2
High risk of bias 4463 54 636 (9·0%) 8·3% (6·7–10·1%) 7·8% (6·2–9·6%) 41 62–37 084 16 30 (8·7%) 96·4
Total 52 067 606 232 (100%) 8·4% (7·9–8·9%) 7·5% (7·0–8·0%) 48 31–47 231 77 345 (100%) 98·1
Heterogeneity between subgroups in all subgroup analyses was p<0·0001, except for subpopulation groups of MSM (p=0·0014), sampling methods (p=0·035), diagnostic methods (p=0·129), sample size 
(p=0·873), and AXIS score (p=0·688). MSM=men who have sex with men. *Income levels by World Bank classification at the midpoint of the study period.18 †Classification of legal or illegal was based on the 
situation of the country at the midpoint of the study period. ‡Convenience sampling included data collected by non-profit or charity organisations focused on the needs of MSM or that provide HIV prevention 
services, venue-specific sampling (eg, saunas and bathhouses, clubs, and one-off public events), via internet advertisement, peer recruitment, and any combination of multiple convenience sampling methods. 
§Appraisal tool for Cross-Sectional Studies (risk of study bias assessment). 
Table 2: Subgroup analyses of pooled syphilis prevalence estimates among MSM, 2000–20
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points; n=3648), which contributed 2·0% of all data 
points. Studies using qualitative diagnostic methods 
showed pooled prevalence estimates of 7·7% (7·1–8·2, 
314 data points; n=584 191), and inclusion of studies that 
used quantitative methods did not change overall 
prevalence estimates (7·5%, 7·0–8·0; 345 data points, 
n=606 232). Pooled estimates were not different between 
sample sizes generated with more than 500 participants 
(7·6%; 95% CI 7·0–8·2, 175 data points, n=555 571) and 
sample sizes with 500 or fewer participants (7·5%; 
6·2–8·9, 170 data points, n=50 661). Stratification of 
studies using the AXIS classification system (score 0–10 
vs 11–20), suggests that risk of individual study bias 
did not alter pooled prevalence estimates. Multivariate 
random-effects meta-regression subgroup analyses 
showed that country income level (p=0·0009), HIV 
prevalence (p=0·0004), subpopulation groups of MSM 
(p<0·0001), and legality of same-sex acts (p<0·0001) 
might be a source of heterogeneity. Forest plots for 
pooled prevalence estimates with corre sponding 95% CIs 
stratified by SDG region and study period are shown in 
the appendix (pp 13–21).
Discussion
To our knowledge, this is the first systematic review and 
meta-analysis assessing global syphilis prevalence among 
MSM. The number of MSM tested in published studies 
has increased between 2000 and 2020. While the global 
syphilis prevalence among MSM was 7·5% over 20 years, 
SDG regional estimates ranged from 1·9% to 10·6%. 
Global pooled prevalence estimates were lower in 2010–20 
than in 2000–09, whereas pooled prevalence estimates 
were higher in 2015–20 in four of eight SDG regions 
compared with 2010–14. Syphilis prevalence estimates 
were high in studies exclusively involving male sex 
workers, transgender women, and transgender women 
sex workers, and studies in which HIV prevalence was 
greater than 5·0%.
We observed a huge rise in the number of MSM tested 
in published studies, from 185 877 in 2000–09 to 420 355 
in 2010–20, which was reflected by increases in all the 
SDG regions except for Australia and New Zealand. 
Improved access to testing since 2000 has been advanced 
by the availability of rapid point-of-care tests for syphilis, 
which might have contributed to reducing prevalence.21,22 
For example, one serial cross-sectional study among HIV-
positive MSM (113 272 clinic visits in total) and HIV-
negative MSM (246 041 clinic visits in total) in Australia in 
2007–14 reported that increased screening was associated 
with increased detection of early latent syphilis (p<0·0001 
for both HIV-positive and HIV-negative MSM), and 
reductions in secondary syphilis (p=0·0003 for HIV-
positive MSM and p=0·03 for HIV-negative MSM).23,24
The pooled prevalence of syphilis was the lowest 
in low-income countries. This observed relationship 
between wealth and disease burden is difficult to explain. 
Wealth can increase geographical mobility which, in 
turn, could increase opportunities for MSM to engage in 
sexual activity, increasing exposure to syphilis in higher-
income settings. However, increased exposure could be 
offset by better access to syphilis testing and treatment in 
these same settings. Similarly, the relationship between 
syphilis prevalence and laws that criminalise same-
sex acts, including some that include the death penalty 
for homosexuality, needs to be interpreted with caution. 
These laws might have the effect of reducing the 
willingness of individuals to self-identify as MSM and 
engage in sexual activity,18 limiting exposure to syphilis. 
Moreover, the same laws could also discourage the most 
sexually active and at-risk MSM from participating 
in prevalence surveys. In our analyses, 35 (72·9%) of 
48 data points from low-income countries were in sub-
Saharan Africa and Central and Southern Asia. Of these, 
16 (94·1%) of 17 data points from sub-Saharan Africa, 
and 13 (72·2%) of 18 data points from Central and 
Southern Asia were from countries that criminalise 
same-sex sexual acts.
The highest prevalence of syphilis was reported in 
lower-middle-income countries, although upper-middle-
income and high-income countries are areas of concern, 
particularly with reports that suggest syphilis trans-
mission among MSM is increasing.5–9 Multiple factors are 
probably at play, including changes in MSM sexual 
behaviour, as reflected in increasing rates of new 
partner acquisition and concurrent partnerships, mobility 
of the MSM population, and reduced use of condoms due 
to pre-exposure prophylaxis for HIV acquisition.25,26 
One study suggests that annual screening and treatment 
of at least 62% of a population of sexually active MSM is 
necessary to achieve local elimination (defined as less 
than one case per 100 000 people).27 Screening and 
treatment are interventions that, when coupled with other 
prevention methods such as consistent condom use and 
partner notification and treatment, can reduce the burden 
of syphilis among MSM to achieve the targeted reduction 
in global syphilis incidence of 90% by 2030.
Our study has several limitations. Firstly, more than 
third of prevalence data included were based on various 
convenience sampling methods. However, sub analyses 
of the corrected pooled prevalence estimates for each 
category of convenience sampling produced results that 
were similar to the overall pooled prevalence estimates 
for convenience sampling, and results from probability 
sampling were similar to the overall pooled prevalence 
estimate for MSM. A second limitation is the fact that the 
region of Eastern and South-Eastern Asia contributed 
188 (54·5%) of the 345 global survey data points, mainly 
from China (153 data points), and had a pooled prevalence 
of 9·7%. This disproportionate number of data points, 
including one study with 47 231 MSM,28 suggests that 
syphilis surveillance among MSM is common and 
prioritised in Eastern and South-Eastern Asia. However, 
such numbers skew the global pooled prevalence slightly 
upward. Another limitation relates to high heterogeneity 
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across SDG regions and other subgroupings, despite 
correcting the data for diagnostic test differences. Of 345 
data points, 30 were categorised as being at high risk of 
bias, and 18 of 345 were from studies limited to MSM 
who were also male sex workers, transgender women, or 
transgender women sex workers, who appear to be at 
higher risk of syphilis infection when compared with 
other MSM studies. Of 345 data points, 31 were based on 
quantitative diagnostic methods, which showed lower 
prevalence estimates than qualitative methods. However, 
our sensitivity analyses suggest that the prevalence data 
from these data points did not influence our overall 
estimates. Lastly, even when considering the corrected 
prevalence estimates of active syphilis based on the 
global reference standard definition, a positive result 
from a non-treponemal test and treponemal test, 
regardless of non-treponemal titre cutoff, might not 
represent an incident infection. The reference standard 
definition of active syphilis can include some infections 
that are old and already treated. As a result, the proportion 
of cases at any given time could be influenced by the 
local historic prevalence of syphilis. In areas where 
syphilis prevalence has been historically high, we might 
be overestimating infection, and syphilis outbreaks 
might not be detectable until the rise of new cases is 
substantial.
The COVID-19 pandemic has affected MSM sexual 
behaviours, with evidence that sexual activity among 
networks of MSM has reduced because of lockdowns. 
This behaviour change could translate into fewer new 
syphilis infections in the near term.29,30 However, there 
have also been reports30 that MSM have had difficulty 
accessing STI testing and treatment during the 
pandemic, potentially suggesting that fewer syphilis 
cases are being diagnosed, treated, and subtracted from 
the MSM population. In light of these reports, it is 
difficult to know if syphilis prevalence among MSM will 
be indirectly altered by COVID-19. Regardless, syphilis 
prevalence among MSM is unacceptably high both 
globally and in SDG regions, particularly in lower-
middle-income, upper-middle-income, and high-income 
countries where cases appear to be increasing and 
where HIV prevalence is high. Achieving the goal of 
reducing global syphilis incidence by 90% by 2030 will 
require sustained commitment to interventions that can 
accelerate syphilis prevention, screening, and treatment 
in this population.
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